-
Obstructive Sleep Apnea (OSA) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
$6,989.00 – $20,967.00Select optionsGrowth of the Prevalence OSA population will contribute to increasing sales in the OSA therapy market over our forecast period. The increase in the number of patients with obstructive sleep apnea across the globe will be driving the market of OSA. According to a study conducted by the World Health Organization (WHO), the global prevalence of sleep apnea is around 100 million people. In the U.S. alone, the number of people with OSA is around 42 million. One out of five adults in the U.S. has mild OSA, while one out of 15 has moderate to severe OSA. The number of cases with OSA is expected to increase during our forecast period, primarily due to the increasing Prevalence of sleep-related disorders. This is projected to drive the OSA market from 2022 to 2032
-
Neuromyelitis Optica Spectrum Disorder (NMOSD) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsWe see great future treatment opportunity for the NMOSD market because of the launch of the emerging therapies like Telitacicept (RC-Pharma), Ravulizumab (Alexion Pharmaceuticals), SHR1459 (Reistone Biopharma) and others potential therapies, providing the global solution for “optic neuritis with spinal cord manifestations and other neurologic disorders associated with the serum aquaporin-4 immunoglobulin G antibodies”. -
Mitochondrial Epilepsy (MIT-E) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsThe Mitochondrial epilepsy (MIT-E) therapeutic market is expected to increase at a significant rate during the figure time frame, 2022 to 2032. In 2022, the market is developing at a consistent rate and the market is relied upon to ascend over the projected horizon with the rise in adoption strategies by key market players. The therapy market is expected to experience high growth throughout our study period, increasing from 2018 to 2032. -
Metastatic Renal cell carcinoma (mRCC) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsCurrently, tyrosine kinase inhibitors (TKIs) and anti-VEGF antibodies are widely used in first- and second-line treatments for mRCC. Despite the current treatments, there remains the unmet need for early diagnosis and treatment options. Emerging drugs in development like Dovitinib (Allarity Therapeutics) and Savolitinib/ AZD6094 (Astrazeneca), and others will expand the first-line and second-line settings for patients with mRCC and likely to address the current unmet needs for the treatment of mRCC. The upcoming treatment options for mRCC can drive market competition, contributing to budget sustainability and improving patient access to biologic treatments.
-
Metastatic Ovarian Cancer (mOC)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsThe Metastatic Ovarian Cancer (mOC) market is relatively large with highest market share holding drugs in 2022 i.e., Olaparib and Niraparib. By 2032, the market is expected to change due to the loss of patents of the current therapies and the uptake and launch of new therapies. In a mOC treatment setting, the Olaparib will consistently perform and will grasp the highest market share followed by other emerging drugs. The sales of the emerging therapies for the treatment of mOC in the study countries (United States, France, Germany, Italy, Spain, United Kingdom and Japan) will experience high growth over the 2018-2032 study period, adding a value estimated at a total market of $ 5.3 billion by 2032.
-
Lumbar Radiculopathy (Sciatica)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsThe Lumbar Radiculopathy/LSR (Sciatica) therapeutic market is expected to experience high growth throughout our study period, increasing from 2017 to 2030. The main drivers of this growth will be the launch of new drugs in chronic LSR/sciatica setting, e.g., Dexamethasone sodium phosphate gel / SEMDEXA (Scilex Pharmaceuticals), Condoliase / HERNICORE (Seikagaku Corporation / Ferring Pharmaceuticals), ETX-810 (Eliem Therapeutics Inc), Extended-release Clonidine / Clonidine micropellet (Sollis Therapeutics) and extended-release dexamethasone (SpineThera).
-
High grade intraepithelial lesion (HSIL) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
$6,989.00 – $20,967.00 Select options -
ER+/HER2- Metastatic Breast Cancer (mBC)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsThe ER + / HER2- metastatic breast cancer (mBC) market is relatively large with the highest market share holding CDK4 / 6 drugs, e.g. Pfizer’s Ibrance (palbociclib), Novartis’s Kisqali (ribociclib) and Eli Lilly’s Verzenio (abemaciclib). By 2032, these drugs will continue to hold the largest share of the market, but we also expect the market to expand with the addition of new oral SERDs/SARMs/SERMs that will take a combined share of 19.1%, antibody drug conjugates with a share of the 2.9% and AKT inhibitors with a 2.6% share. The sales of the emerging therapies for the treatment of ER+/HER2- mBC in the study countries (United States, France, Germany, Italy, Spain, United Kingdom and Japan) will experience high growth over the 2022-2032 study period, adding a value estimated at a total market of $ 5.6 billion by 2032.
-
Corticobasal Syndrome (CBS) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsCorticobasal syndrome (CBS) is characterized by lowest clinical diagnostic accuracy, with the highest clinical presentation found in corticobasal degeneration (CBD). Current Corticobasal syndrome (CBS) treatment is limited to levodopa, commonly prescribed medication for the treatment of Parkinson’s disease. Thus, there is a huge unmet need for a medical treatment to improve the quality of life. Emerging therapies like Rho-kinase inhibitor- Fasudil (Woolsey Pharmaceuticals) have the potential to overcome the treatment barrier. Corticobasal syndrome market size will reflect high growth from 2025-2030 due to launch of Fausdil (Woolsey) in the market from 2025 year.
-
Complex regional pain syndrome (CRPS)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsComplex regional pain syndrome (CRPS) is a chronic pain condition characterized by spontaneous and evoked regional pain, usually starting in a distal extremity, which is disproportionate in magnitude or duration to the typical pain course after similar tissue trauma. Current treatment for CRPS requires a multidisciplinary approach involving patient education, physical and occupational therapy, psychiatry and pain medicine specialists, along with pharmacological and surgical interventions. Unfortunately, the current available treatment options are generally considered to be ineffective and one-dimensional, as they only treat part of the disease. Emerging therapies like Soticlestat (Takeda / Ovid Therapeutics and Lanicemine (AstraZeneca / Biohaven Pharmaceuticals) is expected to generate more market share than other emerging therapies and have the potential to overcome the treatment barrier.
Call us today: +1 (304) 470-2225
English
You can use WPML or Polylang and their language switchers in this area.
Report Store
Home » Report Store
